Comparative Pharmacology
Head-to-head clinical analysis: JENLOGA versus NORTREL 1 35 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JENLOGA versus NORTREL 1 35 21.
JENLOGA vs NORTREL 1/35-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JENLOGA is a combination of sulfamethoxazole, a sulfonamide, and trimethoprim, a dihydrofolate reductase inhibitor. Sulfamethoxazole inhibits bacterial dihydrofolic acid synthesis by competing with para-aminobenzoic acid, while trimethoprim inhibits dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid. This sequential blockade produces synergistic bactericidal activity.
Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, altering cervical mucus to impede sperm penetration, and inducing endometrial changes that reduce implantation likelihood.
350 mg orally once daily with food.
One tablet orally once daily for 21 days, followed by 7 days off, then repeat.
None Documented
None Documented
Terminal half-life 6-8 hours in healthy adults; prolonged to 12-15 hours in moderate renal impairment (CrCl 30-50 mL/min)
Norethindrone: 5-14 hours; Ethinyl estradiol: 17-24 hours. Steady-state achieved after 10 days.
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites and unchanged drug)
Renal 50-60% as metabolites, fecal 40-50% as conjugates, <1% unchanged
Category C
Category C
Oral Contraceptive
Oral Contraceptive